 |
University of Alabama Birmingham School of Medicine | |
| City: Birmingham | State: AL | |
|
Links:
Commentary:fcoipolicy.pdf UABSOM_Industry_StatementRevised__3_.pdf Guidelines_for_Relationships_with_Industry.pdf Summary: University of Alabama Birmingham School of Medicine has a model policy for speaking, by prohibiting participation in "speaker's bureaus." The scholarships/trainee funds and off-site education policy domains are also strong. Finally, oversight and sanctions are outlined in the policy. The institution could have a higher score with a stronger samples policy that prevents samples from being given directly to physicians and a public disclosure policy of conflicts of interest. Demographics: The University of Alabama at Birmingham School of Medicine has three clinical campuses: Birmingham, Tuscaloosa, and Huntsville. 60% of students complete required clerkships in Birmingham with an even high proportion at this site during the fourth year of the curriculum. Submitted policies apply to all School of Medicine and UAB Health System faculty, staff, and trainees, including medical students and postgraduate medical trainees independent of the hospital or clinic he or she may be currently working. Updates: This institution did not submit any new or additional policies for the 2012-13 AMSA PharmFree Scorecard.This institution's evaluation was last updated: 1/18/2012 |
||
| Gifts & Meals |  |
All gifts and on-site meals are prohibited, with the exception of food as part of CME programming. |
| Consulting relationships |  |
The policy requires prior approval of consulting relationships, however, a formal contract, including provisions to ensure appropriate payment, is not required. |
| Industry-funded speaking relationships | |
The policy explicitly prohibits participation in "speaker's bureaus," and the policy prevents industry from controlling the presentation content. |
| Disclosure | |
The policy requires all personnel to annually file disclosed financial ties. |
| Pharmaceutical samples |  |
The policy does not prevent samples from being given directly to physicians. A stronger, more detailed samples policy is recommended for future submissions. |
| Purchasing & Formularies | |
The policy requires annual disclosure of financial conflicts of interest and case-by-case review for potential conflicts of interest. |
| Industry Sales Representatives | |
The policy requires industry sales representatives to meet with faculty only by appointment. |
| On-campus Education | |
All CME, whether or not accredited, must comply with ACCME standards. Further, funding may not go to the individual, but must be centralized at the departmental or divisional level. This policy could be strengthened by mandating centralization of funds at the institutional, rather than departmental level, and ensuring industry may not select recipient departments. |
| Attendance at Industry-Sponsored Lectures & Meetings Off-Campus | |
The policy explicitly prohibits the receipt of payment by industry for attendance at off-site meetings. However, the policy does not require institutional approval of all travel support. |
| Industry Support for Scholarships & Funds for Trainees | |
Oversight of funds is established through the AMC and at the discretion of the AMC. |
| Medical school curriculum | |
Exemplary policy, mandating all departments train students and staff on conflicts of interest and industry interactions, emphasizing data interpretation techniques and evidence-based medicine. Further, medical education must cover prescribing bias associated with industry representative interaction. |
| Do the policies specify an oversight mechanism? |  |
Noncompliance managed by the Division Director and Department Chair and reported to the Dean's Office. |
| Are there explicit sanctions for noncompliance? | |
Sanctions are referenced |
 | |
 | Model policy |
 | Good progress toward model policy |
 | No policy, or policy unlikely to have a substantial effect on behavior |
 | Did not report |
 | Policy not relevant to this institution (e.g., does not make purchasing decisions) |
